{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:08:26Z","timestamp":1758960506203},"reference-count":54,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1253\/circj.cj-14-1348","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T22:03:29Z","timestamp":1420581809000},"page":"255-262","source":"Crossref","is-referenced-by-count":16,"title":["Dual Antiplatelet Therapy for Coronary Artery Disease"],"prefix":"10.1253","volume":"79","author":[{"given":"Cheol Whan","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Antiplatelet Trialists\u2019 Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. <i>BMJ<\/i> 1994; 308: 81\u2013106.","DOI":"10.1136\/bmj.308.6921.81"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. <i>BMJ<\/i> 2002; 324: 71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. <i>Nat New Biol<\/i> 1971; 231: 232\u2013235.","DOI":"10.1038\/newbio231232a0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. <i>JAMA<\/i> 1980; 243: 661\u2013669.","DOI":"10.1001\/jama.1980.03300330019023"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. <i>Lancet<\/i> 1988; 2: 349\u2013360.","DOI":"10.1016\/S0140-6736(88)92833-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Jackson EA, Sivasubramian R, Spencer FA, Yarzebski J, Lessard D, Gore JM, et al. Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): A population-based perspective. <i>Am Heart J<\/i> 2002; 144: 259\u2013268.","DOI":"10.1067\/mhj.2002.123837"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Paikin JS, Eikelboom JW. Cardiology patient page: Aspirin. <i>Circulation<\/i> 2012; 125: e439\u2013e442, doi:10.1161\/CIRCULATIONAHA.111.046243.","DOI":"10.1161\/CIRCULATIONAHA.111.046243"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. <i>J Clin Invest<\/i> 2004; 113: 340\u2013345.","DOI":"10.1172\/JCI20986"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. <i>Circulation<\/i> 1999; 100: 1667\u20131672.","DOI":"10.1161\/01.CIR.100.15.1667"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cattaneo M. New P2Y(12) inhibitors. <i>Circulation<\/i> 2010; 121: 171\u2013179.","DOI":"10.1161\/CIRCULATIONAHA.109.853069"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. <i>N Engl J Med<\/i> 1989; 321: 501\u2013507.","DOI":"10.1056\/NEJM198908243210804"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Scrutinio D, Cimminiello C, Marubini E, Pitzalis MV, Di Biase M, Rizzon P. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. <i>J Am Coll Cardiol<\/i> 2001; 37: 1259\u20131265.","DOI":"10.1016\/S0735-1097(01)01164-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, et al; African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. <i>JAMA<\/i> 2003; 289: 2947\u20132957.","DOI":"10.1001\/jama.289.22.2947"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). <i>Lancet<\/i> 1996; 348: 1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. <i>N Engl J Med<\/i> 1991; 321: 13\u201317.","DOI":"10.1056\/NEJM199101033240103"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. <i>Circulation<\/i> 1995; 91: 1676\u20131688.","DOI":"10.1161\/01.CIR.91.6.1676"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. <i>N Engl J Med<\/i> 1998; 339: 1665\u20131671.","DOI":"10.1056\/NEJM199812033392303"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. <i>Circulation<\/i> 1999; 99: 2364\u20132366.","DOI":"10.1161\/01.CIR.99.18.2364"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. <i>Lancet<\/i> 2007; 369: 667\u2013678.","DOI":"10.1016\/S0140-6736(07)60314-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. <i>Circulation<\/i> 2008; 117: 261\u2013295.","DOI":"10.1161\/CIRCULATIONAHA.107.188208"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J<\/i> 2010; 31: 2501\u20132555.","DOI":"10.1093\/eurheartj\/ehq277"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. <i>JAMA<\/i> 2005; 293: 2126\u20132130.","DOI":"10.1001\/jama.293.17.2126"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. <i>JAMA<\/i> 2007; 297: 159\u2013168.","DOI":"10.1001\/jama.297.2.joc60179"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, et al. Stent thrombosis after drug-eluting stent implantation: Incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>Eur Heart J<\/i> 2009; 30: 2714\u20132721.","DOI":"10.1093\/eurheartj\/ehp275"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. <i>N Engl J Med<\/i> 2010; 362: 1374\u20131382.","DOI":"10.1056\/NEJMoa1001266"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: A randomized, controlled trial. <i>Circulation<\/i> 2014; 129: 304\u2013312.","DOI":"10.1161\/CIRCULATIONAHA.113.003303"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Collet JP, Silvain J, Barth\u00e9l\u00e9my O, Rang\u00e9 G, Cayla G, Van Belle E, et al; for the ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): A randomised trial. <i>Lancet<\/i> 2014; 384: 1577\u20131585.","DOI":"10.1016\/S0140-6736(14)60612-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. <i>N Engl J Med<\/i> 2014; 371: 2155\u20132166.","DOI":"10.1056\/NEJMoa1409312"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The efficacy of xience\/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. <i>Circulation<\/i> 2012; 125: 505\u2013513.","DOI":"10.1161\/CIRCULATIONAHA.111.059022"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. <i>Circulation<\/i> 2012; 125: 2015\u20132026.","DOI":"10.1161\/CIRCULATIONAHA.111.071589"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti M, Salvatella N, et al. Second generation drug-eluting stents implantation followed by six- versus twelve-month dual antiplatelet therapy: The SECURITY randomized clinical trial. <i>J Am Coll Cardiol<\/i> 2014; 64: 2086\u20132097.","DOI":"10.1016\/j.jacc.2014.09.008"},{"key":"32","unstructured":"32. Schulz-Sch\u00fcpke S, Mehilli J, Laugwitz KL, Neumann FJ, Berg JM, Adriaenssens T, et al. Six versus twelve months of clopidogrel therapy after drug-eluting stenting (ISAR-SAFE Trial). <i>In<\/i>: Proceedings of 2014 American Heart Association Scientific Sessions."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: The RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation). <i>J Am Coll Cardiol<\/i> 2012; 60: 1340\u20131348.","DOI":"10.1016\/j.jacc.2012.06.043"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D\u2019Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. <i>Lancet<\/i> 2012; 379: 1393\u20131402.","DOI":"10.1016\/S0140-6736(12)60324-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. <i>Lancet<\/i> 2013; 382: 614\u2013623.","DOI":"10.1016\/S0140-6736(13)61170-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after Xience V implantation: Results from the 8,061-patient Xience V United States study. <i>JACC Cardiovasc Interv<\/i> 2012; 5: 626\u2013635.","DOI":"10.1016\/j.jcin.2012.02.014"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. <i>Eur Heart J<\/i> 2014; 35: 1949\u20131956.","DOI":"10.1093\/eurheartj\/ehu026"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al; OPTIMIZE Trial Investigators. Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. <i>JAMA<\/i> 2013; 310: 2510\u20132522.","DOI":"10.1001\/jama.2013.282183"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. <i>N Engl J Med<\/i> 2001; 345: 494\u2013502.","DOI":"10.1056\/NEJMoa010746"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. <i>JAMA<\/i> 2002; 288: 2411\u20132420.","DOI":"10.1001\/jama.288.19.2411"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised, placebo-controlled trial. <i>Lancet<\/i> 2005; 366: 1607\u20131621.","DOI":"10.1016\/S0140-6736(05)67660-X"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med<\/i> 2007; 357: 2001\u20132015.","DOI":"10.1056\/NEJMoa0706482"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>N Engl J Med<\/i> 2012; 367: 1297\u20131309.","DOI":"10.1056\/NEJMoa1205512"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med<\/i> 2009; 361: 1045\u20131057.","DOI":"10.1056\/NEJMoa0904327"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. <i>J Am Coll Cardiol<\/i> 2007; 49: 1982\u20131988.","DOI":"10.1016\/j.jacc.2007.03.025"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>Am Heart J<\/i> 2014; 167: 437\u2013444.","DOI":"10.1016\/j.ahj.2013.12.020"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Varenhorst C, Jensevik K, Jernberg T, Sundstr\u00f6m A, Hasvold P, Held C, et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. <i>Eur Heart J<\/i> 2014; 35: 969\u2013978.","DOI":"10.1093\/eurheartj\/eht438"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>Eur Heart J<\/i> 2014; 35: 2541\u20132619.","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines. <i>J Am Coll Cardiol<\/i> 2014; 64: e139\u2013e228, doi:10.1016\/j.jacc.2014.09.017.","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2009; 360: 2066\u20132078.","DOI":"10.1056\/NEJMoa0901301"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Park SJ, Lee CW. Coronary artery disease: Risk models for revascularization: The search continues. <i>Nat Rev Cardiol<\/i> 2012; 9: 316\u2013318.","DOI":"10.1038\/nrcardio.2012.57"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. S\u00f8rensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, J\u00f8rgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data. <i>Lancet<\/i> 2009; 374: 1967\u20131974.","DOI":"10.1016\/S0140-6736(09)61751-7"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Nat Rev Cardiol<\/i> 2014; 11: 597\u2013606.","DOI":"10.1038\/nrcardio.2014.104"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Serruys PW, Chevalier B, Dudek D, Cequier A, Carri\u00e9 D, Iniguez A, et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. <i>Lancet<\/i> 2015; 385: 43\u201354.","DOI":"10.1016\/S0140-6736(14)61455-0"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/79\/2\/79_CJ-14-1348\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T09:13:02Z","timestamp":1566205982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/79\/2\/79_CJ-14-1348\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-14-1348","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}